rachel_ABQ said:Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives: Prior authorization appeal…
Thank you — that is the clearest version of this I have read, and I have read a lot of them. Printing the relevant bit and taking it with me.
From the other side of the consultation, briefly.
My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.
SarahChen_PharmD said:Dr.RaviCardio said: ...compounded vs brand cost and coverage...
Financial impact of cost and coverage weight loss beyond medication cost:
- Groceries: SAVED $250/month (eating less)
- Restaurants: SAVED $160/month (fewer meals out)
- Alcohol: SAVED $110/month (stopped drinking)
- Life insurance: Premium REDUCED by $40/month (lower BMI)
- Copays: SAVED $60/month (fewer BP/cholesterol meds)
Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsMarkLI_maint said:Denials are usually procedural rather than clinical, and the order that works reflects that.
MarkLI_maint said:...regarding the discontinuation data for cost and coverage...
I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."
Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.
This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.